On August 5, 2025, Edwards Lifesciences faced a legal setback as the United States Court of Appeals for the Federal Circuit (CAFC) affirmed a prior ruling against the company. The CAFC upheld the Patent Trial and Appeal Board's (PTAB) December 2022 decision, which maintained the validity of a patent held by Cardiovalve Ltd., a subsidiary of Venus Medtech.
This ruling represents a loss for Edwards in its ongoing patent dispute with Cardiovalve. The outcome could potentially impact Edwards' competitive landscape and intellectual property strategy in the structural heart device market.
The affirmed ruling means that Cardiovalve's patent remains valid, which may affect Edwards' ability to develop or commercialize certain technologies without potential infringement concerns or licensing agreements. This development introduces a degree of uncertainty regarding future competitive dynamics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.